ravulizumab gMG
Selected indexed studies
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. (NEJM Evid, 2022) [PMID:38319212]
- Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. (Eur J Neurol, 2025) [PMID:40241307]
- Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. (J Neurol, 2023) [PMID:36890354]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. (2022) pubmed
- Ravulizumab: A Review in Generalised Myasthenia Gravis. (2023) pubmed
- Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis. (2024) pubmed
- The Efficacy and Safety of Different Targeted Drugs for the Treatment of Generalized Myasthenia Gravis: A Systematic Review and Bayesian Network Meta-analysis. (2024) pubmed
- Long-Term Efficacy and Safety of Ravulizumab in Adults With Anti-Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: Final Results From the Phase 3 CHAMPION MG Open-Label Extension. (2025) pubmed
- Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. (2024) pubmed
- Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis. (2023) pubmed
- Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience. (2025) pubmed
- Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. (2023) pubmed
- Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. (2024) pubmed